You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Colorcon
Moodys
Dow
Johnson and Johnson

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

Claims for Patent: 8,980,242

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,980,242
Title:Aliphatic prodrug linker
Abstract: A polymeric prodrug is described which comprises at least one polymer attached via at least one permanent bond to a bicine linker. The bicine linker is attached via a temporary linkage to an amine containing biologically active moiety. The amine containing biologically active moiety--such as a drug--can be released by cleaving the temporary linkage.
Inventor(s): Vetter; Dirk (Heidelberg, DE), Rau; Harald (Heidelberg, DE), Wegge; Thomas (Heidelberg, DE), Hersel; Ulrich (Heidelberg, DE)
Assignee: Ascendis Pharma GmbH (Hellerup, DK)
Application Number:11/993,645
Patent Claims:1. A polymeric prodrug comprising: at least one polymer attached via at least one permanent bond to a bicine linker, the bicine linker being attached via a temporary linkage to an amine containing biologically active moiety; wherein the prodrug has the following structure: ##STR00018## and wherein: T is D; D is a residue of an amine containing biologically active moiety; X is a spacer moiety; R2 and R3 are independently selected from the group consisting of hydrogen, acyl groups, and protecting groups for hydroxyl groups; R4 to R12 are independently selected from the group consisting of hydrogen, X--R1, substituted and non-substituted linear, branched and cyclical C.sub.1 to C.sub.8 alkyls and heteroalkyls, aryls, substituted aryls, substituted and nonsubstituted heteroaryls, cyano, nitro, halogen, carboxy, and carboxamide; and R1 is a polymer.

2. The prodrug of claim 1; wherein the biologically active moiety is selected from the group consisting of small molecule biologically active agents and biopolymers.

3. The prodrug of claim 2; wherein the biologically active moiety is a biopolymer selected from the group consisting of proteins, polypeptides, oligonucleotides, and peptide nucleic acids.

4. The prodrug of claim 3; wherein the biopolymer is a polypeptide selected from the group consisting of ACTH, adenosine deaminase, agalsidase, albumin, alpha-1 antitrypsin (AAT), apha-1 proteinase inhibitor (API), alteplase, anistreplase, ancrod serine protease, antibodies (monoclonal and polyclonal, and fragments and fusions), antithrombin III, antitrypsins, aprotinin, asparaginases, biphalin, bone-morphogenic proteins, calcitonin (salmon), collagenase, DNase, endorphins, enfuvirtide, enkephalins, erythropoietins, factor VIIa, factor VIII, factor VIIIa, factor IX, fibrinolysin, fusion proteins, follicle-stimulating hormones, granulocyte colony stimulating factor (G-CSF), galactosidase, glucagon, glucagon-like peptides, glucocerebrosidase, granulocyte macrophage colony stimulating factor (GM-CSF), phospholipase-activating protein (PLAP), gonadotropin chorionic (hCG), hemoglobins, hepatitis B vaccines, hirudin, hyaluronidases, idurnonidase, immune globulins, influenza vaccines, interleukins (1 alpha, 1 beta, 2, 3, 4, 6, 10, 11, 12), IL-1 receptor antagonist (rhIL-1ra), insulins, interferons (alpha 2a, alpha 2b, alpha 2c, beta 1a, beta 1b, gamma 1a, gamma 1b), keratinocyte growth factor (KGF), transforming growth factors, lactase, leuprolide, levothyroxine, luteinizing hormone, lyme vaccine, natriuretic peptide, pancrelipase, papain, parathyroid hormone, PDGF, pepsin, platelet activating factor acetylhydrolase (PAF-AH), prolactin, protein C, octreotide, secretin, sermorelin, superoxide dismutase (SOD), somatropins (growth hormone), somatostatin, streptokinase, sucrase, tetanus toxin fragment, tilactase, thrombins, thymosin, thyroid stimulating hormone, thyrotropin, tumor necrosis factor (TNF), TNF receptor-IgG Fc, tissue plasminogen activator (tPA), TSH, urate oxidase, urokinase, vaccines, and plant protein.

5. The prodrug of claim 3; wherein the biopolymer is a protein prepared by recombinant DNA technology.

6. The prodrug of claim 3; wherein the biopolymer is a protein selected from the group consisting of antibody fragments, single chain binding proteins, catalytic antibodies, and fusion proteins.

7. The prodrug of claim 3; wherein the biopolymer is a protein selected from the group consisting of antibodies, calcitonin, G-CSF, GM-CSF, erythropoietin, hemoglobins, interleukins, insulins, interferons, SOD, somatropin, TNF, TNF-receptor-IgG Fc, and glucagon-like peptides.

8. The prodrug of claim 2; wherein the biologically active moiety is a small molecule biologically active agent selected from the group consisting of central nervous system-active agents, anti-infective, anti-neoplastic, antibacterial, anti-fungal, analgesic, contraceptive, anti-inflammatory, steroidal, vasodilating, vasoconstricting, and cardiovascular agents with at least one primary or secondary amino group.

9. The prodrug of claim 2; wherein the biologically active moiety is a small molecule biologically active agent selected from the group consisting of daunorabicin, doxorubicin, idarubicin, mitoxantron, aminoglutethimide, amantadine, diaphenylsulfon, ethambutol, sulfadiazin, sulfamerazin, sulfamethoxazol, sulfalen, clinafioxacin, moxifloxacin, ciprofloxaxin, enoxacin, norfloxacin, neomycin B, sprectinomycin, kanamycin A, meropenem, dopamin, dobutamin, lisinopril, serotonin, acivicin and carbutamid.

10. The prodrug of claim 1; wherein R4 to R12 are independently selected from hydrogen, and substituted and non-substituted linear, branched and cyclical C.sub.1 to C.sub.8 alkyls and heteroalkyls.

11. The prodrug of claim 1; wherein R1 is selected from the group consisting of polyalkyloxy-based polymers, dextran, chitosan, hyaluronic acid and derivatives, alginate, xylan, mannan, carrageenan, agarose, cellulose, starch, hydroxyethyl starch (HES) and other carbohydrate-based polmers, poly(vinyl alcohols), poly(oxazolines), poly(anhydrides), poly(ortho esters), poly(carbonates), poly(urethanes), poly(acrylic acids), poly(acrylamides), poly(acrylates), poly(methacrylates), poly(siloxanes), poly(vinylpyrrolidone), poly(cyanoacrylates), poly(esters), poly(iminocarbonates), poly(amino acids), collagen, gelatin, copolymers, grafted copolymers, cross-linked polymers, and block copolymers from the above listed polymers.

12. The prodrug of claim 1; wherein R1 is a hydrogel.

13. The prodrug of claim 1; wherein R1 is a branched or hyperbranched polymer.

14. The prodrug of claim 1; wherein R1 is a dendrimer or dense star polymer.

15. The prodrug of claim 1; wherein R1 is a biopolymer.

16. The prodrug of claim 1; herein wherein R1 is a protein.

17. The prodrug of claim 3; wherein the protein is albumin, an antibody, fibrin, casein or any other plasma protein.

18. The prodrug of claim 1; wherein R1 further includes one or more biologically active substances.

19. The prodrug of claim 1; wherein R1 has at least one functional group for linkage to X.

20. The prodrug of claim 19; wherein the at least one functional group is selected from the group consisting of carboxylic acid and activated derivatives, amino, maleimide, thiol, sulfonic acid and derivatives, carbonate and derivatives, carbamate and derivatives, hydroxyl, aldehyde, ketone, hydrazine, isocyanate, isothiocyanate, phosphoric acid and derivatives, phosphonic acid and derivatives, haloacetyl, alkyl halides, acryloyl, arylating agents, hydroxylamine, disulfides, vinyl sulfone, vinyl ketone, diazoalkanes, diazoacetyl compounds, epoxide, oxirane, and aziridine.

21. The prodrug of claim 19; wherein the at least one functional group is selected from the group consisting of thiol, maleimide, amino, carboxylic acid and derivatives, carbonate and derivatives, carbamate and derivatives, aldehyde, and haloacetyl.

22. The prodrug of claim 1; wherein the bond or group formed between X and R1 is selected from the group consisting of disulfide, S-succinimido, amide, amino, carboxylic ester, sulphonamide, carbamate, carbonate, ether, thioether, imine, oxime, hydrazone, urea, thiourea, phosphate, and phosphonate.

23. The prodrug of claim 1; wherein the bonds or groups formed between X and R1 is selected from the group consisting of S-succinimido, amide, carbamate, thioether, and urea.

24. A method for the synthesis of a polymeric prodrug of claim 1, comprising: providing a starting molecule of Formula III: ##STR00019## displacing A with a starting molecule of Formula II: ##STR00020## cleaving the resulting intermediate from the solid phase and cleaving all present protecting groups to form an intermediate of Formula V: ##STR00021## and attaching a polymer R1 to X in the intermediate of Formula V to form the polymeric prodrug of claim 1; wherein: D is a residue of an amine containing biologically active moiety; X is a spacer moiety; R2 and R3 are independently selected from the group consisting of hydrogen, acyl groups, and protecting groups for hydroxyl groups; R4 to R12 are independently selected from the group consisting of hydrogen, X--R1, substituted and non-substituted linear, branched and cyclical C.sub.1 to C.sub.8 alkyls and heteroalkyls, aryls, substituted aryls, substituted and nonsubstituted heteroaryls, cyano, nitro, halogen, carboxy, and carboxamide; and R1 is a polymer.

25. A method for the synthesis of a polymeric prodrug of claim 1, comprising: providing a starting molecule of Formula VI: ##STR00022## forming an intermediate of Formula VII by at least one substitution or reductive alkylation step, where the Formula VII is: ##STR00023## cleaving the intermediate of Formula II from the solid phase and cleaving all present protecting groups to form an intermediate of Formula VIII: ##STR00024## and attaching a polymer R1 to X in the intermediate of Formula VII to form the polymeric prodrug of claim 1; wherein: D is a residue of an amine containing biologically active moiety; X is a spacer moiety; R2 and R3 are independently selected from the group consisting of hydrogen, acyl groups, and protecting groups for hydroxyl groups; R4 to R12 are independently selected from the group consisting of hydrogen, X--R1, substituted and non-substituted linear, branched and cyclical C.sub.1 to C.sub.8 alkyls and heteroalkyls, aryls, substituted aryls, substituted and nonsubstituted heteroaryls, cyano, nitro, halogen, carboxy, and carboxamide; and R1 is a polymer.

26. A method for the synthesis of a polymeric prodrug of claim 1, comprising: providing a starting molecule of Formula IX: ##STR00025## forming an intermediate of Formula X by at least one substitution or reductive alleviation step, where Formula X is: ##STR00026## cleaving the intermediate of Formula X from the solid phase without cleaving all present protecting groups to form an intermediate of Formula XI: ##STR00027## activating intermediate of Formula XI with a activating reagent to form an intermediate of Formula XII: ##STR00028## reacting intermediate of Formula XII with an amine containing drug D to form an intermediate of Formula XIII, and ##STR00029## and attaching a polymer R1 to X in the intermediate of Formula XIII after cleavage of the protecting group PG to form the polymeric prodrug of claim 1; wherein: D is a residue of an amine containing biologically active moiety; A is a leaving group; X is a spacer moiety; R2 and R3 are independently selected from the group consisting of hydrogen, acyl groups, and protecting groups for hydroxyl groups; R4 to R12 are independently selected from the group consisting of hydrogen, X--R1, substituted and non-substituted linear, branched and cyclical C.sub.1 to C.sub.8 alkyls and heteroalkyls, aryls, substituted aryls, substituted and nonsubstituted heteroaryls, cyano, nitro, halogen, carboxy, and carboxamide; and R1 is a polymer.

27. A method for the synthesis of a polymeric prodrug of claim 1, comprising: providing a starting molecule of Formula XI: ##STR00030## attaching a polymer R1 to X in the intermediate of Formula XI after cleavage of the protecting group PG to form an intermediate of formula XIV: ##STR00031## activating intermediate of Formula XIV with a activating reagent to form a polymeric prodrug reagent of Formula XV: ##STR00032## and reacting intermediate of Formula XV with an amine containing drug D to form the polymeric prodrug of claim 1; wherein: D is a residue of an amine containing biologically active moiety; A is a leaving group; X is a spacer moiety; R2 and R3 are independently selected from the group consisting of hydrogen, acyl groups, and protecting groups for hydroxyl groups; R4 to R12 are independently selected from the group consisting of hydrogen, X--R1, substituted and non-substitutedlinear, branched and cyclical C.sub.1 to C.sub.8 alkyls and heteroalkyls, aryls, substituted aryls, substituted and nonsubstituted heteroaryls, cyano, nitro, halogen, carboxy, and carboxamide; and R1 is a polymer.

28. A method for the synthesis of a polymeric prodrug of claim 1, comprising: providing a starting molecule of Formula XII: ##STR00033## attaching a polymer R1 to X in the intermediate of Formula XII after cleavage of the protecting group PG to form a polymeric linker reagent of formula XV: ##STR00034## and reacting the intermediate of Formula XV with an amine containing drug D to form the polymeric prodrug of claim 1; wherein: D is a residue of an amine containing biologically active moiety; A is a leaving group; X is a spacer moiety; R2 and R3 are independently selected from the group consisting of hydrogen, acyl groups, and protecting groups for hydroxyl groups; R4 to R12 are independently selected from the group consisting of hydrogen, X--R1, substituted and non-substituted linear, branched and cyclical C.sub.1 to C.sub.8 alkyls and heteroalkyls, aryls, substituted aryls, substituted and nonsubstituted heteroaryls, cyano, nitro, halogen, carboxy, carboxamide; and R1 is a polymer.

29. The method of claim 26; wherein the activating agent is a carbodiimide N-hydroxysuccinimide mixture.

30. The method of claim 26; wherein A is selected from the group consisting of chloride, bromide, fluoride, nitrophenoxy, imidazolyl, N-hydroxysuccinimidyl, N-hydroxybenzotriazolyl, N-hydroxylazobenzotriazolyl, pentafluorphenoxy, and N-hydroxysulfosuccinimidyl.

31. A method for hydrolysing the prodrug of claim 1, comprising: a step of placing the prodrug in solution with a pH of approximately 7.4.

32. The method of claim 31; wherein the solution is an extra-cellular fluid.

33. A method of administration of an amine-containing moiety to a living organism comprising: a first step of providing a polymeric prodrug according to claim 1; a second step of administering the polymeric prodrug to the living organism; and a third step of cleaving the amine-containing moiety from the polymeric prodrug by means of a substantially non-enzymatic reaction.

34. The method of claim 33; wherein the amine-containing moiety is a biologically active moiety.

35. The method of claim 33; wherein the biologically active moiety is selected from the group consisting of small molecule biologically active agents and biopolymers.

36. The prodrug of claim 35; wherein the biologically active moiety is a biopolymer selected from the group consisting of proteins, polypeptides, oligonucleotides and peptide nucleic acids.

37. The method of claim 36; wherein the biopolymer is a polypeptide selected from the group consisting of ACTH, adenosine deaminase, agalsidase, albumin, apha-1 antitrypsin (AAT), apha-1 proteinase inhibitor (API), alteplase, anistreplase, ancrod serine protease, antibodies (monoclonal and polyclonal, and fragments and fusions), antithrombin III, antitrypsins, aprotinin, asparaginases, biphalin, bone-morphogenic proteins, calcitonin (salmon), collagenase, DNase, endorphins, enfuvirtide, enkephalins, erythropoietins, factor VIIa, factor VIII, factor VIIIa, factor IX, fibrinolysin, fusion proteins, follicle-stimulating hormones, granulocyte colony stimulating factor (G-CSF), galactosidase, glucagon, glucagon-like peptides, glucocerebrosidase, granulocyte macrophage colony stimulating factor (GM-CSF), phospholipase-activating protein (PLAP), gonadotropin chorionic (hCG), hemoglobins, hepatitis B vaccines, hirudin, hyaluronidases, idurnonidase, immune globulins, influenza vaccines, interleukins (1 alpha, 1 beta, 2, 3, 4, 6, 10, 11, 12), IL-1 receptor antagonist (rhIL-1ra), insulins, interferons (alpha 2a, alpha 2b, alpha 2c, beta 1a, beta 1b, gamma 1a, gamma 1b), keratinocyte growth factor (KGF), transforming growth factors, lactase, leuprolide, levothyroxine, luteinizing hormone, lyme vaccine, natriuretic peptide, pancrelipase, papain, parathyroid hormone, PDGF, pepsin, platelet activating factor acetylhydrolase (PAF-AH), prolactin, protein C, octreotide, secretin, sermorelin, superoxide dismutase (SOD), somatropins (growth hormone), somatostatin, streptokinase, sucrase, tetanus toxin fragment, tilactase, thrombins, thymosin, thyroid stimulating hormone, thyrotropin, tumor necrosis factor (TNF), TNF receptor-IgG Fc, tissue plasminogen activator (tPA), TSH, urate oxidase, urokinase, vaccines, and plant protein.

38. The method of claim 36; wherein the biopolymer is a protein prepared by recombinant DNA technology.

39. The method of claim 36; wherein the biopolymer is a protein selected from the group consisting of antibody fragments, single chain binding proteins, catalytic antibodies, and fusion proteins.

40. The method of claim 35; wherein the biologically active moiety is a small molecule biologically active agent selected from the group consisting of central nervous system-active agents, anti-infective, anti-neoplastic, antibacterial, anti-fungal, analgesic, contraceptive, anti-inflammatory, steroidal, vasodilating, vasoconstricting, and cardiovascular agents with at least one primary or secondary amino group.

41. The method of claim 35; wherein the biologically active moiety is a small molecule biologically active agent selected from the group consisting of daunorabicin, doxorubicin, idarabicin, mitoxantron, aminoglutethimide, amantadine, diaphenylsulfon, ethambutol, sulfadiazin, sulfamerazin, sulfamethoxazol, sulfelen, clinafloxacin, moxifloxacin, ciptofloxaxin, enoxaci[alpha], norfloxacin, neomycin B, sprectinomycin, kanamycin A, meropenem, dopamin, dobutamin, lisinopril, serotonin, acivicin, and carbutamid.

42. The method of claim 33; wherein the third step is carried out in an extra-cellular fluid.

43. The method of claim 33; wherein the substantially non-enzymatic reaction comprises a step of hydrolysis.

44. A method of reacting the polymeric prodrug according to claim 1, comprising: cleaving the amine-containing moiety from the carrier by a substantially non-enzymatic reaction of the nucleophile-containing linker.

45. The method of claim 44; wherein the substantially non-enzymatic reaction is carried out at a pH of approximately 7.4.

46. The method of claim 44; wherein the amine-containing moiety attached to the carrier is cleaved in an extra-cellular fluid.

47. The method of claim 44; wherein the substantially non-enzymatic reaction comprises a step of hydrolysis.

48. The method of claim 44; wherein the amine-containing moiety is a biologically active moiety.

49. A method of providing a therapeutically useful concentration of a biologically active molecule comprising: cleaving, in vivo, the biologically active molecule from the prodrug according to claim 1.

50. The prodrug of claim 11; wherein R1 is a polyalkyloxy-based polymer selected from the group consisting of polypropylene glycol) and poly(ethylene glycol).

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0512705.5Jun 22, 2005
PCT Information
PCT FiledJune 21, 2006PCT Application Number:PCT/EP2006/063418
PCT Publication Date:December 28, 2006PCT Publication Number:WO2006/136586

Details for Patent 8,980,242

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 004 1975-06-26   Start Trial Ascendis Pharma GmbH (Hellerup, DK) 2025-06-22 DISCN search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 006 1975-06-26   Start Trial Ascendis Pharma GmbH (Hellerup, DK) 2025-06-22 DISCN search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 007 1975-06-26   Start Trial Ascendis Pharma GmbH (Hellerup, DK) 2025-06-22 DISCN search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 009 1975-06-26   Start Trial Ascendis Pharma GmbH (Hellerup, DK) 2025-06-22 DISCN search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 010 1975-06-26   Start Trial Ascendis Pharma GmbH (Hellerup, DK) 2025-06-22 DISCN search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Colorcon
McKinsey
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.